Thank you for the insightful #MovingForwardInfectionDiagnostics meeting today. Great discussions around #TPP target product profile and how diagnostic innovations can help improve patient outcomes @HCAILeeds @BIVDA @NHSEngland @LeedsBRC

Don’t forget todays @ESCMID ESGCD Xmas webinar today on all things Cdiff! 3pm CET, link 👇 Hear the cases presented and vote on the winner! #Cdiff @FfitzP Link to join the webinar:

Research should be informed by a diversity of public experiences and insights so that it leads to treatments and services that reflect these needs. Find out more about the 'Inclusive Opportunities' standard, and reflect on whether you're meeting it: https://t.co/60ZgRxWLnR

Today is the first face to face event for Leeds Female Leaders since the pandemic @LeedsWomen1 Looking forward to seeing everyone there and having some great discussions on the future of the network! #nervous #excited @drjanefreeman @amk762 @LeedsHospitals @LeedsMedHealth

Today's the day! We're here at the beautiful Royal College of Physicians for our 'Challenges of Urinary Tract Infections' conference #BSACUTI2023. We're looking forward to an inspiring and thought-provoking day! https://t.co/Zh9N0rzukI

The next in ⁦@ESCMID⁩ C.difficile study group webinar from our Back to Basics series; listening to the patient voice is today at 5pm CET. See below for link to join. #CDI #Cdiff

Interested in #cdiff? Interested in addressing inequality in diagnosis or treatment? This is the PhD opportunity for you! Come and join the ⁦@HCAILeeds⁩ group in Leeds. #HCAI #CDI ⁦@UniversityLeeds⁩ ⁦@LeedsHospitals⁩

Some new FMT drugs approved in USA. Informed consent is key!

Bezlotoxumab may be FMT sparing (though withdrawn in UK). Tapered vancomycin is probably better the FMT. Cost in UK is much less than the costs in clinical trials. There appears to be some better donors than others.

Treatment should be based on previous Cdiff treatments

Long term safety has no been proven. @OpenBiome has no control arm. 97% rejection rate for donors. Lots of safety warnings.

Mark Wilcox on the efficacy and safety of #Cdifficile and #FMT has a cure rate of 67% #bsacspring2023 @HCAILeeds

"I'm pleased that our feedback is useful, but what are you going to do with it?" Important point from one of our #Publiccontributors today when talking about #PPI activity #Bepartofresearch #Internationalclinicaltrialsday #Patientandpublicinvolvement

NICE early value assessment of rapid #UTI #AMR diagnostics published today https://t.co/Bqo6VlRjZP @BSACandJAC @UKCPAPIN @biainfection @HCAILeeds @DrKieranHand @nesta_uk @longitude_prize @ESGAP_ABS @BIVDA

Many #amr interventions fail at the implementation stage. This review helps to address this. @NIHRresearch @NIHRCRN_yorks @NIHRCRN_NENCumb @DrDianeAshiru @DrKieranHand @AMRatLEEDS @HCAILeeds @UKCPAPIN @biainfection @MartinLlewelyn @CarrolEnitan @CTRCardiffUni @e_charani

An Infectious disease specialist from US refer to the ESCMID guideline on CDI treatment...excellent presentation of Erik Dubberke at annual NNMM meeting on microbiota interventions @EurFmt @CMIJournal @jvanprehn

Great to be back with colleagues in Leeds for #ISpySepsis conference. #IPC #sepsis and #AMR are aligned. #IPC #vaccination #hygeine helps to prevent #sepsis but #antibiotic use drives #AMR. Partnership working, not silo is key @ISpySepsis @UKSepsisTrust @LCH_IPC @HWLeeds

Come and join the first of our new Back to Basics webinar series from ⁦@ESCMID⁩ ESGCD Tomorrow at 4pm CET brush up on #diagnosis of #CDiff infection. Open to all, just use the link on the page below ⁦@FfitzP⁩ ⁦@EdKuijper2⁩ #CDI

4/4 Research is vital to ensuring that we give our patients the best and most up-to-date care locally, nationally and internationally. I am passionate about supporting those in research careers and would love for all HCS to get the chance to drive change through research.